{"id":949759,"date":"2026-04-08T07:04:21","date_gmt":"2026-04-08T11:04:21","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/climb-bio-to-host-rd-spotlight-webcast-highlighting-budoprutug-and-the-cd19-opportunity-on-may-5-2026\/"},"modified":"2026-04-08T07:04:21","modified_gmt":"2026-04-08T11:04:21","slug":"climb-bio-to-host-rd-spotlight-webcast-highlighting-budoprutug-and-the-cd19-opportunity-on-may-5-2026","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/climb-bio-to-host-rd-spotlight-webcast-highlighting-budoprutug-and-the-cd19-opportunity-on-may-5-2026\/","title":{"rendered":"Climb Bio to Host R&amp;D Spotlight Webcast Highlighting Budoprutug and the CD19 Opportunity on May 5, 2026"},"content":{"rendered":"<div class=\"mw_release\">\n<p>WELLESLEY HILLS, Mass., April  08, 2026  (GLOBE NEWSWIRE) &#8212; Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases, today announced details for the next installment of their R&amp;D Spotlight Series &#8211; a budoprutug webcast event, which is set for Tuesday, May 5, 2026, at 8:00 a.m. ET.<\/p>\n<p>The event will highlight the Company\u2019s budoprutug program, a clinical-stage, anti-CD19 monoclonal antibody with the potential to address a broad range of B-cell mediated, immune-driven diseases. Budoprutug is being evaluated in clinical trials for primary membranous nephropathy (pMN), immune thrombocytopenia (ITP), and systemic lupus erythematosus (SLE). Additionally, a clinical trial evaluating a subcutaneous (SC) formulation of budoprutug in healthy volunteers recently completed dosing.<\/p>\n<p>Climb Bio\u2019s management team will be joined by David Jayne, MD, Professor of Clinical Autoimmunity at the University of Cambridge and Director\u00a0of the\u00a0Vasculitis and Lupus Service at Addenbrooke\u2019s Hospital.<\/p>\n<p>The budoprutug event will feature:<\/p>\n<ul type=\"disc\">\n<li>An overview of CD19 as a target for B-cell mediated disease<\/li>\n<li>Scientific rationale and potential commercial opportunity for budoprutug in pMN, ITP, and SLE<\/li>\n<li>Design of ongoing studies and dose selection<\/li>\n<li>Details on the Company\u2019s development strategy for budoprutug<\/li>\n<\/ul>\n<p>\n        <strong>Webcast Information<\/strong><br \/>\n        <br \/>The live webcast will be accessible via the \u201cNews &amp; Events\u201d section of the Climb Bio website: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=uhVMwKTZdjBtnQ7rAGsth__BPAp4UaKGXhPKQjJkOguHX5kcZ9llrq7L_dsa3vE6uQ4g8PsSU2m3fK9umRxOl1kumo9S6wYMLhaUdRfyt4w=\" rel=\"nofollow\" target=\"_blank\">https:\/\/ir.climbbio.com\/<\/a>. A webcast replay will be available on the Climb Bio website beginning approximately two hours after the webcast event and will be archived for at least 30 days.<\/p>\n<p>\n        <strong>About Climb Bio, Inc.<\/strong><br \/>\n        <br \/>Climb Bio, Inc. is a clinical-stage biotechnology company with a mission to deliver high impact, disease-modifying medicines for individuals living with immune-mediated diseases, including those affecting kidney health. The Company\u2019s pipeline includes, budoprutug, an anti-CD19 monoclonal antibody that has potential to treat a broad range of B-cell mediated diseases, and CLYM116, an anti-APRIL monoclonal antibody being developed for IgA nephropathy. For more information, please visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=81FmQMGU2-Tl9Y4Yr_yTdw3pz0Q96zpSdH4UNX8v0afWpixUR3D3A8dqg6OxAQggC4vT8YPAWscC-VTXRSX4a6IDTylu2ErS5D2HxQQ7mKh_c9nTyk9i770I1q8ATXOyjjOpHZxm9JJQQ7NzHkocgMIz7EPHCacBx_rC3VGpVUmLV2Kk89DhBkp-Gi4Mnm93dEW3jeVAzoX7M4NaFS1BI2Lg5qiu41j249Lwe-0vZzo=\" rel=\"nofollow\" target=\"_blank\">climbbio.com<\/a>.\u00a0<\/p>\n<p>\n        <strong>About Budoprutug<\/strong><br \/>\n        <br \/>Budoprutug is a clinical-stage, anti-CD19 monoclonal antibody with the potential to address a broad range of B-cell mediated, immune-driven diseases. Designed with enhanced effector function and low picomolar affinity, budoprutug targets and depletes CD19-expressing B cells, including plasmablasts and certain plasma cells, key sources of pathogenic autoantibodies. Early clinical data suggest budoprutug may offer durable B-cell depletion, rapid reductions in autoantibodies, and clinical remission in primary membranous nephropathy (pMN). Budoprutug is being evaluated in clinical trials for pMN, immune thrombocytopenia (ITP), and systemic lupus erythematosus (SLE). A subcutaneous formulation is also in development to enable broader patient access. Budoprutug has been granted Orphan Drug Designation and Fast Track Designation by the FDA for the treatment of pMN.<\/p>\n<p>\n        <strong>Forward-Looking Statements<\/strong><br \/>\n        <br \/>This press release contains \u201cforward-looking statements\u201d within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation statements regarding: future expectations, plans and prospects for Climb Bio; expectations regarding the therapeutic benefits, clinical potential and clinical development of budoprutug; <u>plans for the development strategy for budoprutug; potential commercial opportunity for budoprutug in primary membranous nephropathy, immune thrombocytopenia, systemic lupus erythematosus<\/u>; the sufficiency of Climb Bio\u2019s cash resources for the period anticipated; and other statements containing the words \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccontinue,\u201d \u201ccould,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cintend,\u201d \u201cmay,\u201d \u201cplan,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cshould,\u201d \u201csuggest,\u201d \u201ctarget,\u201d \u201cwould,\u201d \u201cwill,\u201d \u201cworking\u201d and similar expressions. Forward-looking statements are based on management\u2019s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in, or implied by, such forward-looking statements. Climb Bio may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. These risks and uncertainties include, but are not limited to, important risks and uncertainties associated with: the ability of Climb Bio to timely and successfully achieve or recognize the anticipated benefits of its acquisition of Tenet Medicines, Inc. and its license agreement with Mabworks; changes in applicable laws or regulation; the possibility that Climb Bio may be adversely affected by other economic, business and\/or competitive factors; Climb Bio\u2019s ability to advance budoprutug and CLYM116 on the timelines expected or at all and to obtain and maintain necessary approvals from the U.S. Food and Drug Administration and other regulatory authorities; obtaining and maintaining the necessary approvals from investigational review boards at clinical trial sites and independent data safety monitoring boards; replicating in clinical trials positive results found in early-stage clinical trials; competing successfully with other companies that are seeking to develop treatments for primary membranous nephropathy, immune thrombocytopenia, systemic lupus erythematosus, IgA nephropathy and other immune-mediated diseases; maintaining or protecting intellectual property rights related to budoprutug, CLYM116 and\/or its other product candidates; managing expenses; and raising the substantial additional capital needed, on the timeline necessary, to continue development of budoprutug, CLYM116 and any other product candidates Climb Bio may develop. For a discussion of other risks and uncertainties, and other important factors, any of which could cause Climb Bio\u2019s actual results to differ materially from those contained in the forward-looking statements, see the \u201cRisk Factors\u201d section, as well as discussions of potential risks, uncertainties and other important factors, in Climb Bio\u2019s most recent filings with the U.S. Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent Climb Bio\u2019s views as of the date hereof and should not be relied upon as representing Climb Bio\u2019s views as of any date subsequent to the date hereof. Climb Bio anticipates that subsequent events and developments will cause Climb Bio\u2019s views to change. However, while Climb Bio may elect to update these forward-looking statements at some point in the future, Climb Bio specifically disclaims any obligation to do so, except as required by law.\u00a0<\/p>\n<p>\n        <strong>Investors and Media<\/strong><br \/>\n        <br \/>Carlo Tanzi, Ph.D.<br \/>Kendall Investor Relations<br \/>ctanzi@kendallir.com<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4NTgxNCM3NTI0MzU3IzIyMDk1NDY=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/MmFjMjk0OTItNDE5Yi00OWVkLWIxZDQtMjI4YzE0MmQ0NDJmLTEyMjEwOTktMjAyNi0wNC0wOC1lbg==\/tiny\/Climb-Bio-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>WELLESLEY HILLS, Mass., April 08, 2026 (GLOBE NEWSWIRE) &#8212; Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases, today announced details for the next installment of their R&amp;D Spotlight Series &#8211; a budoprutug webcast event, which is set for Tuesday, May 5, 2026, at 8:00 a.m. ET. The event will highlight the Company\u2019s budoprutug program, a clinical-stage, anti-CD19 monoclonal antibody with the potential to address a broad range of B-cell mediated, immune-driven diseases. Budoprutug is being evaluated in clinical trials for primary membranous nephropathy (pMN), immune thrombocytopenia (ITP), and systemic lupus erythematosus (SLE). Additionally, a clinical trial evaluating a subcutaneous (SC) formulation of budoprutug in healthy volunteers recently completed dosing. Climb Bio\u2019s management team will &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/climb-bio-to-host-rd-spotlight-webcast-highlighting-budoprutug-and-the-cd19-opportunity-on-may-5-2026\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Climb Bio to Host R&amp;D Spotlight Webcast Highlighting Budoprutug and the CD19 Opportunity on May 5, 2026&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-949759","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Climb Bio to Host R&amp;D Spotlight Webcast Highlighting Budoprutug and the CD19 Opportunity on May 5, 2026 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/climb-bio-to-host-rd-spotlight-webcast-highlighting-budoprutug-and-the-cd19-opportunity-on-may-5-2026\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Climb Bio to Host R&amp;D Spotlight Webcast Highlighting Budoprutug and the CD19 Opportunity on May 5, 2026 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"WELLESLEY HILLS, Mass., April 08, 2026 (GLOBE NEWSWIRE) &#8212; Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases, today announced details for the next installment of their R&amp;D Spotlight Series &#8211; a budoprutug webcast event, which is set for Tuesday, May 5, 2026, at 8:00 a.m. ET. The event will highlight the Company\u2019s budoprutug program, a clinical-stage, anti-CD19 monoclonal antibody with the potential to address a broad range of B-cell mediated, immune-driven diseases. Budoprutug is being evaluated in clinical trials for primary membranous nephropathy (pMN), immune thrombocytopenia (ITP), and systemic lupus erythematosus (SLE). Additionally, a clinical trial evaluating a subcutaneous (SC) formulation of budoprutug in healthy volunteers recently completed dosing. Climb Bio\u2019s management team will &hellip; Continue reading &quot;Climb Bio to Host R&amp;D Spotlight Webcast Highlighting Budoprutug and the CD19 Opportunity on May 5, 2026&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/climb-bio-to-host-rd-spotlight-webcast-highlighting-budoprutug-and-the-cd19-opportunity-on-may-5-2026\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-08T11:04:21+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4NTgxNCM3NTI0MzU3IzIyMDk1NDY=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/climb-bio-to-host-rd-spotlight-webcast-highlighting-budoprutug-and-the-cd19-opportunity-on-may-5-2026\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/climb-bio-to-host-rd-spotlight-webcast-highlighting-budoprutug-and-the-cd19-opportunity-on-may-5-2026\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Climb Bio to Host R&amp;D Spotlight Webcast Highlighting Budoprutug and the CD19 Opportunity on May 5, 2026\",\"datePublished\":\"2026-04-08T11:04:21+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/climb-bio-to-host-rd-spotlight-webcast-highlighting-budoprutug-and-the-cd19-opportunity-on-may-5-2026\\\/\"},\"wordCount\":992,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/climb-bio-to-host-rd-spotlight-webcast-highlighting-budoprutug-and-the-cd19-opportunity-on-may-5-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY4NTgxNCM3NTI0MzU3IzIyMDk1NDY=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/climb-bio-to-host-rd-spotlight-webcast-highlighting-budoprutug-and-the-cd19-opportunity-on-may-5-2026\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/climb-bio-to-host-rd-spotlight-webcast-highlighting-budoprutug-and-the-cd19-opportunity-on-may-5-2026\\\/\",\"name\":\"Climb Bio to Host R&amp;D Spotlight Webcast Highlighting Budoprutug and the CD19 Opportunity on May 5, 2026 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/climb-bio-to-host-rd-spotlight-webcast-highlighting-budoprutug-and-the-cd19-opportunity-on-may-5-2026\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/climb-bio-to-host-rd-spotlight-webcast-highlighting-budoprutug-and-the-cd19-opportunity-on-may-5-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY4NTgxNCM3NTI0MzU3IzIyMDk1NDY=\",\"datePublished\":\"2026-04-08T11:04:21+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/climb-bio-to-host-rd-spotlight-webcast-highlighting-budoprutug-and-the-cd19-opportunity-on-may-5-2026\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/climb-bio-to-host-rd-spotlight-webcast-highlighting-budoprutug-and-the-cd19-opportunity-on-may-5-2026\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/climb-bio-to-host-rd-spotlight-webcast-highlighting-budoprutug-and-the-cd19-opportunity-on-may-5-2026\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY4NTgxNCM3NTI0MzU3IzIyMDk1NDY=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY4NTgxNCM3NTI0MzU3IzIyMDk1NDY=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/climb-bio-to-host-rd-spotlight-webcast-highlighting-budoprutug-and-the-cd19-opportunity-on-may-5-2026\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Climb Bio to Host R&amp;D Spotlight Webcast Highlighting Budoprutug and the CD19 Opportunity on May 5, 2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Climb Bio to Host R&amp;D Spotlight Webcast Highlighting Budoprutug and the CD19 Opportunity on May 5, 2026 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/climb-bio-to-host-rd-spotlight-webcast-highlighting-budoprutug-and-the-cd19-opportunity-on-may-5-2026\/","og_locale":"en_US","og_type":"article","og_title":"Climb Bio to Host R&amp;D Spotlight Webcast Highlighting Budoprutug and the CD19 Opportunity on May 5, 2026 - Market Newsdesk","og_description":"WELLESLEY HILLS, Mass., April 08, 2026 (GLOBE NEWSWIRE) &#8212; Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases, today announced details for the next installment of their R&amp;D Spotlight Series &#8211; a budoprutug webcast event, which is set for Tuesday, May 5, 2026, at 8:00 a.m. ET. The event will highlight the Company\u2019s budoprutug program, a clinical-stage, anti-CD19 monoclonal antibody with the potential to address a broad range of B-cell mediated, immune-driven diseases. Budoprutug is being evaluated in clinical trials for primary membranous nephropathy (pMN), immune thrombocytopenia (ITP), and systemic lupus erythematosus (SLE). Additionally, a clinical trial evaluating a subcutaneous (SC) formulation of budoprutug in healthy volunteers recently completed dosing. Climb Bio\u2019s management team will &hellip; Continue reading \"Climb Bio to Host R&amp;D Spotlight Webcast Highlighting Budoprutug and the CD19 Opportunity on May 5, 2026\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/climb-bio-to-host-rd-spotlight-webcast-highlighting-budoprutug-and-the-cd19-opportunity-on-may-5-2026\/","og_site_name":"Market Newsdesk","article_published_time":"2026-04-08T11:04:21+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4NTgxNCM3NTI0MzU3IzIyMDk1NDY=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/climb-bio-to-host-rd-spotlight-webcast-highlighting-budoprutug-and-the-cd19-opportunity-on-may-5-2026\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/climb-bio-to-host-rd-spotlight-webcast-highlighting-budoprutug-and-the-cd19-opportunity-on-may-5-2026\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Climb Bio to Host R&amp;D Spotlight Webcast Highlighting Budoprutug and the CD19 Opportunity on May 5, 2026","datePublished":"2026-04-08T11:04:21+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/climb-bio-to-host-rd-spotlight-webcast-highlighting-budoprutug-and-the-cd19-opportunity-on-may-5-2026\/"},"wordCount":992,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/climb-bio-to-host-rd-spotlight-webcast-highlighting-budoprutug-and-the-cd19-opportunity-on-may-5-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4NTgxNCM3NTI0MzU3IzIyMDk1NDY=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/climb-bio-to-host-rd-spotlight-webcast-highlighting-budoprutug-and-the-cd19-opportunity-on-may-5-2026\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/climb-bio-to-host-rd-spotlight-webcast-highlighting-budoprutug-and-the-cd19-opportunity-on-may-5-2026\/","name":"Climb Bio to Host R&amp;D Spotlight Webcast Highlighting Budoprutug and the CD19 Opportunity on May 5, 2026 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/climb-bio-to-host-rd-spotlight-webcast-highlighting-budoprutug-and-the-cd19-opportunity-on-may-5-2026\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/climb-bio-to-host-rd-spotlight-webcast-highlighting-budoprutug-and-the-cd19-opportunity-on-may-5-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4NTgxNCM3NTI0MzU3IzIyMDk1NDY=","datePublished":"2026-04-08T11:04:21+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/climb-bio-to-host-rd-spotlight-webcast-highlighting-budoprutug-and-the-cd19-opportunity-on-may-5-2026\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/climb-bio-to-host-rd-spotlight-webcast-highlighting-budoprutug-and-the-cd19-opportunity-on-may-5-2026\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/climb-bio-to-host-rd-spotlight-webcast-highlighting-budoprutug-and-the-cd19-opportunity-on-may-5-2026\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4NTgxNCM3NTI0MzU3IzIyMDk1NDY=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4NTgxNCM3NTI0MzU3IzIyMDk1NDY="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/climb-bio-to-host-rd-spotlight-webcast-highlighting-budoprutug-and-the-cd19-opportunity-on-may-5-2026\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Climb Bio to Host R&amp;D Spotlight Webcast Highlighting Budoprutug and the CD19 Opportunity on May 5, 2026"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/949759","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=949759"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/949759\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=949759"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=949759"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=949759"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}